A 48-Week, Randomized Controlled Trial of Doravirine for Individuals With HIV and Obesity on Integrase Inhibitors and Tenofovir Alafenamide: The Do IT Study (ACTG A5391)
Abstract
Abstract Background Integrase inhibitors (INSTI) and tenofovir alafenamide (TAF) have been associated with greater weight gain compared to nonnucleoside reverse transcriptase inhibitors (NNRTIs) and tenofovir disoproxil fumarate (TDF), but the effects of an antiretroviral regimen switch on weight are unclear. Methods This 48-week, 3–parallel group, open-label, multicenter, randomized controlled trial (NCT04636437) in people with HIV and obesity on an INSTI (bictegravir, dolutegravir, or raltegravir) with TAF/emtricitabine (FTC) assessed whether switching to the NNRTI doravirine (DOR) with TAF/FTC or TDF/FTC results in weight loss or stabilization. Treatment effects were estimated using linear regression adjusted for sex, race, and entry weight. Results Of the 147 participants randomized, 145 initiated their assigned treatment. At entry, median age was 49 years; body mass index was 34.9 kg/m2, and time on INSTI + TAF/FTC was 3.4 years; 49% were female and 53% Black. After 48 weeks, the estimated mean change in weight was −0.47% (95% CI: −2.09, 1.14) for the DOR + TAF/FTC arm, −2.73% (−4.22, −1.23) for DOR + TDF/FTC, and −1.84% (−3.37, −0.30) for INSTI + TAF/FTC. The estimated mean difference in weight change at 48 weeks for DOR versus INSTI (both with TAF/FTC) was 1.36 percentage points (97.5% CI: −1.20, 3.92) and −0.89 percentage points (−3.34, 1.57) for DOR + TDF/FTC versus INSTI + TAF/FTC. There was no evidence of variation by sex or race, nor of treatment differences for…
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design. Reported size: 147 participants or records.
Read the paper
Related studies
- Global, regional, and national burden of hepatitis B, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019
- A meta‐analysis of anal cancer incidence by risk group: Toward a unified anal cancer risk scale
- Global fertility in 204 countries and territories, 1950–2021, with forecasts to 2100: a comprehensive demographic analysis for the Global Burden of Disease Study 2021
- Exercise interventions in Alzheimer's disease: A systematic review and meta-analysis of randomized controlled trials
- Prognostic Significance of Carbonic Anhydrase IX Expression in Cancer Patients: A Meta-Analysis
- Glucocorticoid Resistance: Is It a Requisite for Increased Cytokine Production in Depression? A Systematic Review and Meta-Analysis
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.